These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 23428001)

  • 1. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
    Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
    Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
    Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
    Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
    Charliński G; Wiater E; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of myeloma in patients not eligible for transplantation.
    Jagannath S
    Curr Treat Options Oncol; 2005 May; 6(3):241-53. PubMed ID: 15869735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
    Picot J; Cooper K; Bryant J; Clegg AJ
    Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V; Palumbo A
    Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].
    Adam Z; Ozábalová E; Němec P; Bedáňová H; Kuman M; Krejčí J; Špinarová L; Žampachová V; Čermáková Z; Pour L; Krejčí M; Sanecká V; Štork M; Pika T; Straub J; Adamová D; Stavařová Y; Král Z; Mayer J
    Vnitr Lek; 2018; 64(4):441-449. PubMed ID: 29791180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
    Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [AL amyloidosis].
    Gadó K; Domján G
    Orv Hetil; 2012 Apr; 153(15):563-73. PubMed ID: 22472357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
    Nagano S; Mori M; Kato A; Ono Y; Aoki K; Arima H; Takiuchi Y; Tabata S; Yanagita S; Matsushita A; Ishikawa T; Imai H; Takahashi T
    Intern Med; 2013; 52(10):1101-5. PubMed ID: 23676598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.